TrialJournal of diabetes investigation2018

Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.

Yutaka Seino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.